"Hydrazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substituted derivatives of hydrazine (formula H2N-NH2).
Descriptor ID |
D006834
|
MeSH Number(s) |
D02.442
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hydrazines".
Below are MeSH descriptors whose meaning is more specific than "Hydrazines".
This graph shows the total number of publications written about "Hydrazines" by people in this website by year, and whether "Hydrazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1998 | 0 | 1 | 1 |
2003 | 0 | 2 | 2 |
2004 | 1 | 0 | 1 |
2005 | 3 | 1 | 4 |
2006 | 2 | 0 | 2 |
2007 | 0 | 1 | 1 |
2008 | 1 | 0 | 1 |
2009 | 2 | 1 | 3 |
2010 | 2 | 0 | 2 |
2011 | 2 | 1 | 3 |
2012 | 0 | 1 | 1 |
2014 | 1 | 2 | 3 |
2015 | 1 | 0 | 1 |
2016 | 2 | 0 | 2 |
2017 | 2 | 1 | 3 |
2018 | 2 | 3 | 5 |
2019 | 2 | 0 | 2 |
2020 | 2 | 0 | 2 |
2021 | 6 | 4 | 10 |
2022 | 1 | 1 | 2 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydrazines" by people in Profiles.
-
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. Am J Hematol. 2024 Apr; 99(4):562-569.
-
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol. 2023 01; 168:76-82.
-
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol. 2022 08 01; 40(22):2479-2490.
-
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. Haematologica. 2021 11 01; 106(11):2853-2858.
-
Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Mol Cancer Ther. 2021 12; 20(12):2352-2361.
-
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study. Invest New Drugs. 2022 04; 40(2):290-299.
-
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. Invest New Drugs. 2022 02; 40(1):124-133.
-
Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol. BMJ Open. 2021 08 27; 11(8):e044885.
-
Anamorelin combined with physical activity, and nutritional counseling for cancer-related fatigue: a preliminary study. Support Care Cancer. 2022 Jan; 30(1):497-509.
-
Interference of eltrombopag with bilirubin measurements on the Vitros 5600 analyzer. J Clin Lab Anal. 2021 Aug; 35(8):e23796.